Trial Profile

A Phase 1b/2Study of Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss (MANTRA-4)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 23 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Milademetan (Primary)
Indications Solid tumours
Focus Adverse reactions
Acronyms MANTRA-4
Sponsors Rain Oncology

Most Recent Events

16 Oct 2023 Status changed from planning to withdrawn prior to enrolment.
30 May 2023 According to a Rain Oncology media release, company plans to terminate the planned Phase 1/2 MANTRA-4 combination trial.
11 May 2023 According to Rain Oncology media release, the company expects to commence trial in mid-2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com